中文

← All funding rounds

Bioptimus

EuropeScience models and AI scientistsParis, FrancePrivate

Website · bioptimus.com ↗

Builds foundation models of biology, starting with pathology images (H-Optimus) and a multimodal model (M-Optimus), and is assembling a large spatial tissue atlas (STELA) to train them.

Disclosed total$76M
Rounds on record2
Latest round$41MRound (unnamed) · 2025-01-14
Last stated valuationNone stated
Investors named16
Research on record1highest level 2 · Computed

Money and evidence

Moneyeach round in US dollars; ≈ converted at its date202420252026$35M$41MEvidencelevel of each research entry12345
Closed roundResearch entry, at its level

Latest round, Round (unnamed), 2025-01-14: the record then held no research entry for the company. The first research entry is dated 2026-04-17; the highest level so far is 2 (Computed).

Rounds and research, on one timeline

  1. 2026-04-17
    Research

    Level 2 · Computed

    Bioptimus reports its pathology model H-optimus-1 ranks first on two outside benchmarks, but 14th of 23 on tissue segmentation

    A stained tissue slide is the most common record of a cancer. A model that turns any slide into general-purpose features lets a hospital or drugmaker build a biomarker test from a smaller labelled set. H-optimus-1 is Bioptimus's main model, free for academic use since February 2025, and the poster's case is that benchmarks run by other groups, not only its own tests, put it at or near the top.

    Timeline entry →doi.org ↗

  2. 2025-01-14Round (unnamed)
    Round

    $41M

    For: multimodal platform, pharma partnerships, more datasets

    Models and platformCommercial roll-outData generation

    The release does not name the stage; the $76M in its headline is the cumulative total including the $35M seed.

    Lead · Cathay Innovation ✓Sofinnova Partners ✓Bpifrance Large VentureAndera Partners ✓Hitachi Ventures ✓Boom Capital VenturesThomas Wolf (angel)SunriseEmmanuel Cassimatis (angel)

    On the deal: Emmanuel Cassimatis (Angel investor); Jacky Abitbol (Partner, Cathay Innovation); Thomas Wolf (Angel investor)

    The investor's own page says · Andera Partners: 12.2024 (andera Life Sciences)

    The investor's own page says · Hitachi Ventures: Series A

    Announced by the company · bioptimus.com ↗

  3. 2024-02-20Seed
    Round

    $35M

    For: build a multi-scale foundation model of biology

    Models and platform

    Lead · Sofinnova Partners ✓Bpifrance Large VentureFrst ✓Cathay Innovation ✓Headline ✓OwkinXavier NielHummingbirdNJF CapitalTop Harvest Capital

    On the deal: Edward Kliphuis (Partner, Sofinnova Partners); Laurent Higueret (Senior Investment Director, Bpifrance Large Venture); Xavier Niel (Individual investor)

    The investor's own page says · Frst: Seed

    Announced by the company · bioptimus.com ↗

Research entries are the timeline's graded entries that name this company. A level grades one claim, not the company, and a blank can mean the record has not caught up rather than that nothing was published.

See these rounds in the table →

On the investors' own sites

Investors that name this company on their own site, in a portfolio or their own announcement. A ✓ in a round marks the same investor.

Its investors also backed

Other companies on this page whose rounds name the same investor.